Skip to content

Summit Therapeutics

US · SMMT #1207 by market cap Listed 2015
9.95 -0.62 -5.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 1 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.2 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
21.19% -0.15pp
Institutions
347 -1
As of
2026/Q4 vs. prior period

Holder types

Individual/Insider76.77%
Mutual Fund9.25%
Hedge Fund6.99%
Public Company4.45%
Private Company0.21%
Sovereign Wealth Fund0.18%
Other2.06%

Top holders as of 2026-11-16

Robert Duggan 71.76% · 573.88M sh
Mahkam Zanganeh 4.58% · 36.63M sh
Baker Bros. Advisors LP 4.10% · 32.79M sh
Akeso, Inc. 4.01% · 32.06M sh
BlackRock 1.30% · 10.36M sh
Vanguard Capital Management, LLC 1.03% · 8.26M sh
FMR 1.02% · 8.14M sh
Vanguard Portfolio Management, LLC 0.84% · 6.72M sh
UBS Asset Management 0.67% · 5.32M sh
State Street Global Advisors 0.76% · 6.09M sh
T. Rowe Price Group, Inc. 0.66% · 5.30M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 49 buys · 0 sells

NameRoleStake
Robert Duggan Co-CEO & Executive Chairman 71.76%
Mahkam Zanganeh Co-Chief Executive Officer 4.58%
Manmeet Soni COO, CFO & Director 0.40%
Bhaskar Anand Chief Accounting Officer & Head of Finance 0.02%
Jeffrey Huber Independent Director 0.01%
Kenneth Clark Lead Independent Director --
Robert F. Booth Independent Director --
Mostafa Ronaghi Independent Director --
Alessandra Cesano Independent Non-Executive Director --
Akeso, Inc. -- --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-07 Bhaskar Anand Chief Accounting Officer & Head of Finance Other Acquisition +100,000 --
2026-06-11 Robert Duggan Co-CEO & Executive Chairman Open Market Acquisition +3,810,000 $13.12
2026-06-03 Mahkam Zanganeh Co-Chief Executive Officer Open Market Acquisition +100,000 $14.60
2026-06-03 Manmeet Soni COO, CFO & Director Open Market Acquisition +50,000 $14.43–14.46
2026-01-07 Bhaskar Anand Chief Accounting Officer & Head of Finance Other Derivative Acquisition +30,000 $18.83
2026-01-01 Kenneth Clark Lead Independent Director Other Derivative Acquisition +52,796 $17.52
2026-01-01 Robert F. Booth Independent Director Other Derivative Acquisition +42,180 $17.52
2026-01-01 Robert Duggan Co-CEO & Executive Chairman Other Derivative Acquisition +11,232 $17.52
2026-01-01 Jeffrey Huber Independent Director Other Derivative Acquisition +44,885 $17.52
2026-01-01 Mostafa Ronaghi Independent Director Other Derivative Acquisition +35,000 $17.52
2026-01-01 Mahkam Zanganeh Co-Chief Executive Officer Other Derivative Acquisition +11,232 $17.52
2026-01-01 Alessandra Cesano Independent Non-Executive Director Other Derivative Acquisition +38,219 $17.52
2026-01-01 Yu Xia -- Other Derivative Acquisition +35,000 $17.52
2025-10-20 Robert Duggan Co-CEO & Executive Chairman Private Acquisition +13,980,789 $18.74
2025-10-20 Mahkam Zanganeh Co-Chief Executive Officer Private Acquisition +293,488 $18.74
2025-10-20 Manmeet Soni COO, CFO & Director Private Acquisition +53,361 $18.74
2025-10-20 Akeso, Inc. -- Private Acquisition +533,617 $18.74
2025-10-20 Bhaskar Anand Chief Accounting Officer & Head of Finance Private Acquisition +26,680 $18.74
2025-09-17 Bhaskar Anand Chief Accounting Officer & Head of Finance Other Derivative Acquisition +50,000 $19.23
2025-09-10 Robert Duggan Co-CEO & Executive Chairman Open Market Acquisition +338,394 $17.68–18.07

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.

Summit Therapeutics discussion 0 comments

Add a comment